Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mr MRto Enable Physicians to Easily Access Information: Mr Tanimura of So-net M3
April 23, 2001
- REGULATORY NEWS IN BRIEF
April 23, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 23, 2001
- Marketing of Half-strength Preparations of Digoxin Expected
April 23, 2001
- Fujisawa, ORIX Capital Establishes New Investment Fund
April 23, 2001
- OBITUARY
April 23, 2001
- Eisai Subscribes to Incyte Genomics"Databases
April 23, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 23, 2001
- Mochida, Maruishi to Jointly Develop Capsaicin-based Cream
April 23, 2001
- Lilly's Gemzar Approved for Pancreatic Cancer Treatment
April 23, 2001
- Pharmacia's Zyvox Approved
April 23, 2001
- First Int'l GL for COPD Published
April 23, 2001
- GSK Obtains Import Approval for Alkeran for Injection 50mg
April 23, 2001
- Most Doctors Expect Effective Drugs Will Be Needed for AIDS in 2001: JHSF Survey
April 23, 2001
- Hisamitsu Forms Genofunctionfor Genome-related Business
April 23, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 23, 2001
- Keidanren, Nikkeiren to Discuss Healthcare System for Elderly
April 23, 2001
- WORLD NEWS IN BRIEF
April 23, 2001
- BUSINESS NEWS IN BRIEF -1-
April 23, 2001
- Hac Kimisawa to Open Record-high Number of New Stores
April 23, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…